These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
426 related articles for article (PubMed ID: 33651913)
41. Targeted treatment and immunotherapy in leptomeningeal metastases from melanoma. Geukes Foppen MH; Brandsma D; Blank CU; van Thienen JV; Haanen JB; Boogerd W Ann Oncol; 2016 Jun; 27(6):1138-1142. PubMed ID: 26961150 [TBL] [Abstract][Full Text] [Related]
42. Impact of immunotherapy among patients with melanoma brain metastases managed with radiotherapy. Stokes WA; Binder DC; Jones BL; Oweida AJ; Liu AK; Rusthoven CG; Karam SD J Neuroimmunol; 2017 Dec; 313():118-122. PubMed ID: 29153603 [TBL] [Abstract][Full Text] [Related]
43. Early imaging radioresponsiveness of melanoma brain metastases as a predictor of patient prognosis. Zubatkina I; Ivanov P J Neurosurg; 2018 Aug; 129(2):354-365. PubMed ID: 28841116 [TBL] [Abstract][Full Text] [Related]
44. Melanoma Brain Metastasis: Biology and Therapeutic Advances. Hasanov M; Acikgoz Y; Davies MA Hematol Oncol Clin North Am; 2024 Oct; 38(5):1027-1043. PubMed ID: 38845301 [TBL] [Abstract][Full Text] [Related]
45. Health-related quality of life in patients with melanoma brain metastases treated with immunotherapy. Thompson JR; Lai-Kwon J; Morton RL; Guminski AD; Gonzalez M; Atkinson V; Sandhu S; Brown MP; Menzies AM; McArthur GA; Lo SN; Long GV; Bartula I Immunotherapy; 2023 Jun; 15(8):593-610. PubMed ID: 37132182 [TBL] [Abstract][Full Text] [Related]
46. Impact of radiotherapy administered simultaneously with systemic treatment in patients with melanoma brain metastases within MelBase, a French multicentric prospective cohort. Tétu P; Allayous C; Oriano B; Dalle S; Mortier L; Leccia MT; Guillot B; Dalac S; Dutriaux C; Lacour JP; Saiag P; Brunet-Possenti F; De Quatrebarbes J; Stoebner PE; Legoupil D; Beylot-Barry M; Lesimple T; Aubin F; Dreno B; Mohamed S; Ballon A; Porcher R; Lebbe C Eur J Cancer; 2019 May; 112():38-46. PubMed ID: 30909072 [TBL] [Abstract][Full Text] [Related]
48. Impact of Novel Treatments in Patients with Melanoma Brain Metastasis: Real-World Data. Derks SHAE; Jongen JLM; van der Meer EL; Ho LS; Slagter C; Joosse A; de Jonge MJA; Schouten JW; Oomen-de Hoop E; van den Bent MJ; van der Veldt AAM Cancers (Basel); 2023 Feb; 15(5):. PubMed ID: 36900253 [TBL] [Abstract][Full Text] [Related]
49. The treatment of melanoma brain metastases before the advent of targeted therapies: associations between therapeutic choice, clinical symptoms and outcome with survival. Vecchio S; Spagnolo F; Merlo DF; Signori A; Acquati M; Pronzato P; Queirolo P Melanoma Res; 2014 Feb; 24(1):61-7. PubMed ID: 24121190 [TBL] [Abstract][Full Text] [Related]
57. Treating brain metastases in melanoma: What is the optimal CNS-directed and systemic management? Wilson TG; Winter H; Taylor H; Herbert C J Radiosurg SBRT; 2021; 7(4):279-285. PubMed ID: 34631229 [TBL] [Abstract][Full Text] [Related]
59. Are prognostic indices for brain metastases of melanoma still valid in the stereotactic era? Badakhshi H; Engeling F; Budach V; Ghadjar P; Zschaeck S; Kaul D Radiat Oncol; 2018 Jan; 13(1):3. PubMed ID: 29316943 [TBL] [Abstract][Full Text] [Related]
60. Survival of patients with melanoma brain metastasis treated with stereotactic radiosurgery and active systemic drug therapies. Choong ES; Lo S; Drummond M; Fogarty GB; Menzies AM; Guminski A; Shivalingam B; Clarke K; Long GV; Hong AM Eur J Cancer; 2017 Apr; 75():169-178. PubMed ID: 28236768 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]